Orchestra BioMed Holdings (OBIO) Non Operating Income (2024)
Orchestra BioMed Holdings (OBIO) reported Non Operating Income of -$11000.0 for Q1 2024.
Orchestra BioMed Holdings (OBIO) has 1 years of Non Operating Income data on file, last reported at -$11000.0 in Q1 2024.
- Quarterly Non Operating Income changed N/A year-over-year to -$11000.0 in Q1 2024, while the trailing twelve-month figure through Dec 2024 was -$11000.0 (changed N/A YoY) and the FY2024 annual result came in at -$11000.0, changed N/A from the prior year.
- Non Operating Income steadied at -$11000.0 in Q1 2024 per OBIO's latest filing.
- Across five years, Non Operating Income topped out at -$11000.0 in Q1 2024 and bottomed at -$11000.0 in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Orchestra BioMed Holdings | 245.24 Mn | 255.02 Mn | 78,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -11,000.00 |